CN103479714B - The novelty teabag of YUPINGFENG KELI - Google Patents
The novelty teabag of YUPINGFENG KELI Download PDFInfo
- Publication number
- CN103479714B CN103479714B CN201310446193.9A CN201310446193A CN103479714B CN 103479714 B CN103479714 B CN 103479714B CN 201310446193 A CN201310446193 A CN 201310446193A CN 103479714 B CN103479714 B CN 103479714B
- Authority
- CN
- China
- Prior art keywords
- yupingfeng
- keli
- nasopharyngeal carcinoma
- group
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of novelty teabag of YUPINGFENG KELI; Aim to provide one and effectively treat nasopharyngeal carcinoma, and the medicine that side effect is little, and expand the range of application of YUPINGFENG KELI; Its technical essential is: YUPINGFENG KELI is as the application for the treatment of medicine for nasopharyngeal; Belong to medical art.<!--1-->
Description
Technical field
The present invention discloses a kind of novelty teabag of medicine, specifically, is the novelty teabag of YUPINGFENG KELI treatment nasopharyngeal carcinoma; Belong to medical art.
Background technology
Nasopharyngeal carcinoma is the malignant tumor betiding cavum nasopharyngeum top and sidewall, occurred frequently in southern china, has significantly race and Area distribution feature.Because its predilection site is hidden, not easily be found in early days, patient goes to a doctor mainly because the metastasis symptom of nasopharyngeal carcinoma and sign clinically, as cervical lymph node enlargement, headache, tinnitus and diplopia etc., now the state of an illness has arrived middle and advanced stage, loses optimal treatment period.Research shows, the morbidity of nasopharyngeal carcinoma and environmental pollution, inherited genetic factors and Epstein Barr virus (EBV) infect closely related.Clinical treatment is mainly radiotherapy primary tumor, and be aided with the chemotherapy that platinum medicine is master, early stage therapeutic effect is better, five year survival rate is between 50%-70%, but middle and advanced stage effect is undesirable, five year survival rate is only 10%-40%, and the reason mainly cancerous cell whole body many places transfer of patient death, comprises lymph metastasis, Bone tumour etc.
Traditional Chinese Medicine does not have the name of disease of nasopharyngeal carcinoma, but embodies related content in the disease such as " cervical carcinoma with cachexia ", " stony mass behind the ear ", " unendurable headache due to invasion of brain by pathogen ", " nasal sinusitis ", " control brain sand ", " grandular plague ", " epistaxis ", " de-flourish ", " scrofula ".For the generation of nasopharyngeal carcinoma, theory of Chinese medical science is thought " the positive deficiency of vital energy then diagenesis ", " Waike Zhengzong, Orthodox Manual of External Diseases " is thought " in damage gas ", " Yangke Xinde Ji, Experience Gained in Treating External Diseases " proposes " it is withered that battalion loses network ", " Zhang Shi doctor is logical " then says " taking by force in ying-qi ", " the surgery case of horse training " is thought " honor of liver spleen is damaged ", and visible the deficient of " ying-qi " has important effect in the generation of nasopharyngeal carcinoma." surgery is really annotated " sayed: " by being worried, being enraged, the inverse condensation with fire of the stagnation of QI, blood form." pathogenesis of visible nasopharyngeal carcinoma be " positive exogenous pathogen Sheng ", weakened body resistance liver spleen is impaired, ying-qi interior-deficiency, and evil expectorant stasis of blood fire of containing is tied.Its pathogenesis key is " void ", " stasis of blood, " expectorant ".The tcm clinical practice treatment of current nasopharyngeal carcinoma, be mainly the tcm treatment according to syndrome differentiation after chemicotherapy, be in auxiliary treatment status, main purpose improves chemicotherapy curative effect, alleviate chemicotherapy toxicity, to make the life better quality, mostly be large proved recipe that is rotten containing heat-clearing and toxic substances removing, blood circulation promoting and blood stasis dispelling, tonify deficiency, drawing out pus by applying a plaster to the affected part, detumescence sore class Chinese medicine.In experimentation, report Chinese medicine Herba Sarcandrae and extract, Effective Component of Chinese Medicine curcumin, Lobatoside H, nitidine chloride, Hesperidin, emodin etc. and have certain suppression nasopharyngeal carcinoma cell activity or radiotherapy sensitization, relevant anti-nasopharyngeal carcinoma activity need further confirmation.
YUPINGFENG KELI comes from YUPINGFENG SAN in Yuan Dynasty's " danxi's experiential therapy ", be control exterior deficiency spontaneous perspiration through generation recipe, be widely used in the treatment of enhancing human body immunity function, there is the effect of strengthening the body resistance, QI invigorating invigorating middle warmer.YUPINGFENG KELI is that " Chinese Pharmacopoeia " version one in 2010 records kind, and records at 2012 editions National essential drugs lists, ownership internal medicine medication-diaphoretic recipes-classification of strengthening body resistance and relieveing exterior syndrome.
YUPINGFENG KELI is made up of the Radix Astragali, Rhizoma Atractylodis Macrocephalae (parched), Radix Saposhnikoviae three taste medicine, has effect of QI invigorating, consolidating superficial resistance, hidroschesis, and for exterior deficiency, spontaneous perspiration aversion to wind, Mian Se Koushi is white, or the empty susceptible ailment said due to cold or exposure person of body.
Modern study thinks that the function of immune system of the generation development of tumor and host is closely related, often there is the problems such as immunosuppressant, lower for the resistance, repeated infection in tumor patient, improving the immunologic function of tumor patient body, is important measures in treatment and prevention of tumour.Yupingfeng owing to there is obvious castering action to immune system, therefore at tumor area mainly as tonification class medicine in use, white etc. for rising after improving immunity, strengthening the body resistance, chemotherapy.Disclosed Yupingfeng comprises in the application of tumor area at present: Zhang Hongjun etc. report that YUPINGFENG SAN can strengthen the immune merit of S180 sarcoma mice, suppress the growth of S 180 Sarcoma in Tumor-bearing Mice; The Cai Guang report ultra micro Yupingfeng ball such as first can raise the leucocyte level of Cancer Patients during Chemotherapy, obviously improves the syndrome of deficiency of QI related symptoms because of leukopenia caused by chemotherapy.Lin Aiwu etc. report that YUPINGFENG SAN is used for the treatment of tumor post-operation low grade fever spontaneous perspiration, good results.Tang Ying etc. disclose YUPINGFENG SAN and have certain inhibitory action to lotus Hepal-6 liver cancer mouse tumor, during with chemotherapeutic drugs Cisplatin coupling, can play synergism and attenuation.
In a word, Yupingfeng is mainly used for immunity lifting after tumor chemoradiotherapy, to lotus as tonification class medicine by existing disclosing
What the inhibitory action of S180 sarcoma mice, lotus Hepal-6 liver cancer mouse tumor all adopted is animal tumor transplantation model, because the dependency between animal tumor transplantation model and clinical efficacy is strong, generally only for the Preliminary screening of drug candidate.Under normal circumstances, the antitumor effectiveness of medicine is evaluated with people's cancer xenograft model result of the test more reliable.Therefore existing disclosing is implemented with concrete without refering in particular to property for the effect of Yupingfeng in oncotherapy.
The technical problem that the present invention solves is the optimal drug proportioning of clear and definite YUPINGFENG KELI in treatment of nasopharyngeal carcinoma and the effectiveness to treatment of nasopharyngeal carcinoma thereof, comprise and confirm its direct killing action to nasopharyngeal carcinoma cell by In vitro cell experiment, confirm that it is to the prolongation effect of life cycle, to the improvement result of life quality by the experiment of people's cancer xenograft model.Dependent interaction has no other documents or patent report.
At present, this product is also widely used in prevention, treatment respiratory system disease and immunologic function disorder is main various diseases.Zhou Haiyin, Luo Haiyan, Fructus Myricae rubrae rain etc. discloses the purposes of YUPINGFENG KELI treatment recurrent respiratory tract infection in " the routine infantile respiratory tract infection repeatedly clinical observation [J] of YUPINGFENG SAN granule therapy 60 "; Yan Yuhong discloses the purposes of YUPINGFENG SAN treatment chronic urticaria in " discussing YUPINGFENG SAN treatment chronic urticaria [J] randomly "; Wang Tao, Shi Hejian, Wu Zhifen disclose the purposes of YUPINGFENG KELI auxiliary treatment anaphylactoid purpura in " YUPINGFENG SAN associating dipyridamole treatment Anaphylactoid Purpura [J] "; Huang Yue, blue Xiao Ling, Gan Jinmei etc. disclose the purposes of YUPINGFENG KELI treatment acute and chronic rhinitis, allergic rhinitis in " YUPINGFENG KELI treatment acute and chronic rhinitis, the routine observation of curative effect of allergic rhinitis 300 [J] "; Zhu Lingzhi discloses the purposes of YUPINGFENG KELI treatment chronic bronchitis in " observation of curative effect of YUPINGFENG KELI treatment chronic bronchitis and Experience of Nursing [J] "; Cao Jiamei, Yuan Tao, wash sword, and Yu Teng etc. disclose the sick purposes of Yupingfeng capsule for treating corneal ulcer in " clinical observation [J] of Yupingfeng capsule for treating corneal ulcer disease "; Liu Yingzhi, Lin Jingli, Fu Yu etc. disclose the purposes that YUPINGFENG KELI treats recurrent oral ulceration in " YUPINGFENG KELI treatment and food anaphylaxis dependency recurrent oral ulceration observation of curative effect [J] "; Zong Guifen, Wang Ling, Wang Fang etc. disclose the purposes of YUPINGFENG SAN auxiliary treatment viral myocarditis in " YUPINGFENG SAN closes SHENGMAI YIN treatment viral myocarditis 48 example [J] "; Lu Dingguo, Qian Yunyu disclose the purposes of Yupingfeng treatment infant wheezing tracheitis in " Yupingfeng Koufuye control infant wheezing tracheitis 18 example observes [J] "; To the bright purposes disclosing YUPINGFENG KELI auxiliary treatment nephrotic syndrome of children in " YUPINGFENG KELI is to nephrotic syndrome of children course of disease intervention analysis [J] ".
Summary of the invention
For the problems referred to above, the object of the present invention is to provide one effectively to treat nasopharyngeal carcinoma, the medicine YUPINGFENG KELI that side effect is little, and expand YUPINGFENG KELI
shoulduse scope.
For solving the problems of the technologies described above, technical scheme provided by the invention is such: this YUPINGFENG KELI is as the application for the treatment of medicine for nasopharyngeal.
The novelty teabag of above-mentioned YUPINGFENG KELI, the raw material of the medicine activity component of YUPINGFENG KELI and mass ratio are: the Radix Astragali 20 ~ 70%, the Rhizoma Atractylodis Macrocephalae 15 ~ 60%, Radix Saposhnikoviae 10 ~ 35%.
Further, the novelty teabag of above-mentioned YUPINGFENG KELI, is characterized in that, the raw material of the medicine activity component of YUPINGFENG KELI and mass ratio are: be preferably the Radix Astragali 60%, the Rhizoma Atractylodis Macrocephalae 20%, Radix Saposhnikoviae 20%.
Compared with prior art, technical scheme provided by the invention, tool has the following advantages:
1, technical scheme provided by the invention adopts Chinese crude drug to be raw material, under guidance of traditional Chinese medicine theory, by rational proportion, the synergism of each medical material, has good therapeutic effect at anti-nasopharyngeal carcinoma, auxiliary nasopharyngeal carcinoma.YUPINGFENG KELI of the present invention, impaired for Nasopharyngeal Carcinoma Patients weakened body resistance liver spleen, ying-qi interior-deficiency, evil expectorant stasis of blood fire knot of containing waits pathogenic characteristic and establishes, full side's Radix Astragali is sweet, tepor, returns spleen, lung meridian, and effect spleen invigorating invigorating middle warmer, ascending up spleen-Qi and Yang, benefit defend consolidating superficial resistance, diuresis, promoting pus discharge and tissue regeneration strengthening; The Rhizoma Atractylodis Macrocephalae is sweet, bitter, warm, returns spleen, stomach warp, effect invigorating the spleen and benefiting QI, dampness diuresis, hidroschesis, antiabortive; Radix Saposhnikoviae is pungent, sweet, tepor, returns bladder, liver, spleen channel, effect expelling pathogenic wind from the body surface, removing dampness to relieve pain, relieving convulsion.The precise and appropriate compatibility of three medical materials is prepared from YUPINGFENG KELI, solves " void " state of nasopharyngeal carcinoma pathogenic characteristic, plays the effect for the treatment of nasopharyngeal carcinoma, also can work in coordination with chemotherapy and radiation simultaneously.Therefore have also been enlarged the range of application of YUPINGFENG KELI purposes.
2, YUPINGFENG KELI provided by the present invention, can significant prolongation Nasopharyngeal Carcinoma Patients life cycle.
3, YUPINGFENG KELI provided by the present invention, can improve Quality of Life for Patients with Nasopharyngeal Carcinoma.
4, YUPINGFENG KELI provided by the present invention, has direct repression to nasopharyngeal carcinoma cell, the growth of energy Tumor suppression.
Accompanying drawing explanation
Fig. 1 YUPINGFENG KELI is on the impact of nasopharyngeal carcinoma CNE2 cell survival rate;
Fig. 2 YUPINGFENG KELI is on the impact of lotus nasopharyngeal carcinoma nude mice body weight;
Fig. 3 YUPINGFENG KELI is on the impact of lotus nasopharyngeal carcinoma nude mouse tumor volume;
Fig. 4 lotus nasopharyngeal carcinoma nude mice survival curve.
Detailed description of the invention
Below in conjunction with detailed description of the invention; claim of the present invention is described in further detail; but do not form any limitation of the invention, the amendment of any limited number of time made within the scope of the claims in the present invention, still within claims of the present invention.
Embodiment 1
The invention provides the application of YUPINGFENG KELI as treatment medicine for nasopharyngeal.
Wherein: raw material and the mass ratio of the medicine activity component of described YUPINGFENG KELI see table:
Experimental example 1 YUPINGFENG KELI is to the toxicity test of nasopharyngeal carcinoma CNE-2 cell
1 instrument and reagent
1.1 medicine
Take YUPINGFENG KELI 10g(to be prepared from by the raw material of embodiment 1 YUPINGFENG KELI 7 and mass ratio), be dissolved in 50mL distilled water, supersound extraction 30min, get supernatant autoclaving, the ratio in 1: 4 carries out doubling dilution, is made into gradient concentration.
1.2 cell
Nasopharyngeal carcinoma CNE-2 cell, is preserved by Nanfang Medical Univ's institute of oncology's Secondary Culture.
1.3 reagent
RPMI-1640 culture medium, hyclone, pancreatin (0.25%) and tetrazolium bromide (MTT) are GIBCO Products, and MTT powder lucifuge PBS dissolves, and is made into 5mg/ml concentration, and the degerming subpackage of 0.22 micron membrane filter ,-20 DEG C save backup.Dimethyl sulfoxide (prosperous Bioisystech Co., Ltd of Beijing ancient cooking vessel state, Sigma subpackage).
1.4 instrument
Boxun superclean bench (Shanghai), FormaseriesIIwaterjacketCO2incubator(Thermo), microplate reader (BIO-RAD), living cells work station (CarlZeiss), NikonEclipseTi inverted microscope, NikonEclipse80i fluorescence microscope, high-speed refrigerated centrifuge (Sigma), ultra cold storage freezer (FormaScientific), autoclave sterilizer (HIRAYAMA), pure water instrument (Millipore).
2 test methods
2.1 nasopharyngeal carcinoma cells are cultivated
Nasopharyngeal carcinoma CNE-2 cell routine Secondary Culture, trophophase cell trypsinization of taking the logarithm, makes cell suspension, with 3 × 10 with the RPMI-1640 culture fluid containing 10% hyclone
4the cell density of individual/mL adds in 96 orifice plates, and every hole 200 μ L, 37 DEG C, cultivates 24h in 5%CO2 incubator, treat that cell grows up to monolayer, sucking-off culture fluid, adds the Yupingfeng medicinal liquid of gradient concentration, the multiple hole of each concentration 5.Matched group adds the RPMI-1640 culture fluid of equal-volume containing 2% hyclone, and establishes zeroing hole.37 DEG C, cultivate in 5%CO2 incubator, after 72h, by medicinal liquid sucking-off, every hole adds 5mg/mlMTT200 μ L, 37 DEG C, hatches 4h, abandon supernatant in 5%CO2 incubator, every hole adds DMSO200 μ L, and concussion mixing 10min under room temperature, enzyme-linked immunosorbent assay instrument measures absorbance, determined wavelength 490nm.And press formula 5-1 calculating cell survival rate.
Cell survival rate=(medicine group mean absorbance values)/(matched group mean absorbance values) × 100%
3 statistical method
Adopt SPSS18.0 statistical software, One-wayANOVA analyzes the difference of cell survival rate between each drug level group and matched group, and p<0.05 is for having significant difference.And adopt the relation between Regression-probit regression analysis drug level and cell survival rate, calculate cell half survival concentration TC
50.
4 experimental results
4.1 YUPINGFENG KELI are on the impact of nasopharyngeal carcinoma CNE2 cellular morphology
After nasopharyngeal carcinoma CNE2 cell adds the YUPINGFENG KELI medicinal liquid of variable concentrations, there is cytopathy in moiety concentrations group, and show as cytoadherence, wall thickness, change circle, fragmentation, come off, absorbance declines.
4.2 YUPINGFENG KELI are on the impact of nasopharyngeal carcinoma CNE2 cell survival rate
Compared with matched group, consult Fig. 1 and table 1, Yupingfeng group 0.7812mg/ml(p=0.022), 3.125mg/ml(p=0.017), 12.5mg/ml(p=0.001), 50mg/ml(p=0.000) and 200mg/ml(p=0.000) have obvious inhibitory action to nasopharyngeal carcinoma CNE2 cell, and with the increase of Yupingfeng concentration, inhibitory action strengthens, and all the other are various with matched group there was no significant difference (p>0.05); Through regression analysis, obtain regression curve Probit (p)=1.131-0.022x, calculate half cell survival concentration TC accordingly
50=28.68mg/ml.
Table 1 YUPINGFENG KELI is on the impact of nasopharyngeal carcinoma CNE2 cell survival rate
Experimental example 2 YUPINGFENG KELI is to the drug efficacy study of lotus nasopharyngeal carcinoma nude mice
1 instrument and reagent
1.1 reagent
Yupingfeng fluid extract (being prepared from by the raw material of embodiment 1 YUPINGFENG KELI 7 and mass ratio), cisplatin (Qilu Pharmaceutical Co., Ltd., lot number 908027CF)
1.3 cells and animal
Nasopharyngeal carcinoma CNE-2 cell strain to be gone down to posterity preservation by institute of oncology of Nanfang Medical Univ.SPF level BALB/C nude mice, 3-4 week age, female, purchased from Guangdong Medical Lab Animal Center.
1.2 reagent and instrument
RPMI-1640 culture medium, hyclone, pancreatin (0.25%) is GIBCO Products, Boxun superclean bench (Shanghai), FormaseriesIIwaterjacketCO2incubator(Thermo), NikonEclipseTi inverted microscope, NikonEclipse80i fluorescence microscope, high-speed refrigerated centrifuge (Sigma), ultra cold storage freezer (FormaScientific), autoclave sterilizer (HIRAYAMA), pure water instrument (Millipore).
2 experimental techniques
The preparation of 2.1 nasopharyngeal carcinoma CNE-2 model of nude mice bearing tumor
Nasopharyngeal carcinoma CNE-2 cell routine Secondary Culture, trophophase cell trypsinization of taking the logarithm, makes cell suspension, with 1 × 10 with the RPMI-1640 culture fluid (not containing serum) containing matrigel
7the cell density of individual/mL implants nude mice dorsal sc, often only inoculates 0.2mL.Then lay one's hand on every day and inoculation position observation tumor growth situation, with V=1/2 × a × b
2(V represents gross tumor volume, a and b represents the length of tumor and wide respectively.) as gross tumor volume >100mm
3time, tumor bearing nude mice is carried out random packet.
2.2 grouping and administrations
By 32 gross tumor volume >100mm
3tumor bearing nude mice carry out random packet, be divided into model control group, cisplatin group, cisplatin+Yupingfeng group, Yupingfeng group, often organize 8 animals.Divide into groups to start administration the same day.Model control group gavage every day gives distilled water, cisplatin group lumbar injection cisplatin injections, dosage 6mg/kg, Per-Hop behavior 1 time, totally 4 weeks.Cisplatin+Yupingfeng group is except the dose cisplatin such as lumbar injection weekly, and every day, gavage gave Yupingfeng medicinal liquid, dosage 40g crude drug/kg.Yupingfeng group gavage every day gives Yupingfeng medicinal liquid, dosage 40g crude drug/kg.Successive administration 28 days.
2.3 evaluation indexes and detection method
Weigh each group of nude mice body weight in each interval of one day, and measure tumor size, with V=1/2 × a × b
2(V represents gross tumor volume, a and b represents the length of tumor and wide respectively.) calculate gross tumor volume, and calculate Relative tumor rate of increase T/C(%), T/C(%)=T
rTV/ C
rTV× 100%(T
rTVrefer to treatment group RTV, C
rTVrefer to negative control group RTV), RTV(relativetumorvolume) represent relative tumour volume, computing formula is: RTV=V
t/ V
0, wherein V
0gained gross tumor volume is measured, V for dividing during cage administration
tgross tumor volume during for measuring each time.Observation terminates rear stripping tumor tissues, and pathological section is done in HE dyeing.
3 statistical method
Adopt SPSS18.0 statistical software, One-WayANOVA(variance analysis) analyze the difference of body weight and gross tumor volume between each group.P<0.05 indicates significant difference.Kaplan-Meier method is adopted to analyze each group of life cycle.
4 experimental results and discussion
4.1 YUPINGFENG KELI are on the impact of nasopharyngeal carcinoma nude mice body weight
After starting drug treatment, weigh each group of nude mice body weight in each interval of one day, draw body weight-time changing curve, as shown in Figure 2.Matched group was treatment first week, and body weight has increased slightly, and reached about 102% of original body mass, and body weight starts to reduce subsequently, when treatment the 3rd week, dropping to minimum, was about 96% of original body mass, body weight bottom out again subsequently, when treating 4th week, reaches about 101% of original body mass.Yupingfeng group then keeps the increase state of body weight always, whole treatment cycle body weight remains on about 104% of original body mass, be up to 105.79% of original body mass, there is significant difference (p=0.036<0.05) with matched group, illustrate that YUPINGFENG KELI can promote the increase of lotus nasopharyngeal carcinoma nude mice body weight.Cisplatin group is after starting treatment, and compared with matched group, nude mouse is reopened and begun significantly to decline, and when the second weekend for the treatment of, weight loss is about 75% of original body mass, has significant difference with matched group, and occurs that nude mice is dead; The variation tendency of Yupingfeng+cisplatin group body weight and cisplatin group there was no significant difference, but there is not nude mice death condition the period of the day from 1 p.m. to 3 p.m. at treatment second week.Result shows, compared with matched group, YUPINGFENG KELI significantly can increase the body weight of lotus nasopharyngeal carcinoma nude mice, and cisplatin then significantly reduces the body weight of nude mice, shows certain toxic and side effects; Compared with YUPINGFENG KELI is individually dosed with cisplatin with cisplatin combined administration, on nude mice body weight to affect difference not obvious, may be because the toxicity of cisplatin is comparatively large, the body weight of nude mice seriously be reduced, masks the increasing action of YUPINGFENG KELI to nude mice body weight.
4.2 YUPINGFENG KELI are on the impact of lotus nasopharyngeal carcinoma nude mouse tumor volume
After starting drug treatment, in each interval of one day with the size of vernier caliper measurement tumor, with V=1/2 × a × b
2(V represents gross tumor volume, a and b represents the length of tumor and wide respectively.) calculate gross tumor volume, draw tumor volume versus time change curve, measure 28 days altogether, as shown in Figure 3.
In observation period, according to tumor volume versus time curve, the visible prolongation along with the time, each group of gross tumor volume is all progressively increase tendency, compared with matched group, Yupingfeng group (p=0.023), cisplatin group (p=0.005) and Yupingfeng+cisplatin group (p=0.001) gross tumor volume all obviously reduces, and difference has significance (the equal <0.05 of p value).The growth of the remarkable Tumor suppression of the equal energy of administration group is described.But cisplatin group and Yupingfeng+cisplatin group difference are not significantly (p>0.05), we think it may is that the inhibitory action of cisplatin to gross tumor volume is much higher than the inhibitory action of Yupingfeng to gross tumor volume, thus mask jade screen wind action, make tumor volume difference between two groups not remarkable.The each group of Relative tumor rate of increase is in table 2.
Table 2 is the group Relative tumor rate of increase respectively
| Grouping | Relative tumor rate of increase T/C(%) |
| Yupingfeng group | 67.20% |
| Cisplatin group | 35.83% |
| Yupingfeng+cisplatin group | 33.78% |
4.3 YUPINGFENG KELI are on the impact of lotus nasopharyngeal carcinoma nude mice life cycle
Calculate from inoculation nasopharyngeal carcinoma CNE2 cell, observe life cycle, observe 51 days altogether for each group.Consult Fig. 4, table 3, table 4 and table 5, in the observation end of term, cisplatin group nude mice is all dead, and nude mice of control group survival rate is 37.5%, and Yupingfeng group nude mice survival rate is 71.4%, and Yupingfeng+cisplatin group nude mice survival rate is 50%.Between each group, survival rate has significant difference (p=0.001<0.05), and matched group mean survival time (MST) is 48.25 days, and median survival interval is 50 days; Cisplatin group mean survival time (MST) is 37 days, and median survival interval is 36 days.Yupingfeng+cisplatin group mean survival time (MST) is 46 days, and median survival interval is 52 days.Yupingfeng group mean survival time (MST) is 50.714 days, median survival interval >52 days.
When result shows that YUPINGFENG KELI is used alone, there is significant prolongation effect to the life cycle of lotus nasopharyngeal carcinoma nude mice, during with Cisplatin, compared with cisplatin group, also can life cycle of significant prolongation nude mice.
Table 3 nude mice survival rate statistics table
| Grouping | Nude mice quantity (only) | Death nude mice quantity in latter stage (only) | Survival nude mice quantity (only) | Survival rate (%) |
| Cisplatin group | 8 | 8 | 0 | 0.0% |
| Matched group | 8 | 5 | 3 | 37.5% |
| Yupingfeng group | 7 | 2 | 5 | 71.4% |
| Yupingfeng+cisplatin group | 8 | 4 | 4 | 50.0% |
| Amount to | 31 | 19 | 12 | 38.7% |
Average and the median survival interval statistical table of table 4
Totally comparing between table 5 level
In sum, Yupingfeng, for pathogenic characteristic " void " state of pathogenesis of cancer, plays the effect for the treatment of nasopharyngeal carcinoma, also can work in coordination with chemotherapy and radiotherapy in the treatment nasopharyngeal carcinoma simultaneously.
Claims (2)
1. YUPINGFENG KELI is in the purposes of preparation treatment medicine for nasopharyngeal, and the raw material of the medicine activity component of described YUPINGFENG KELI and mass ratio are: the Radix Astragali 20 ~ 70%, the Rhizoma Atractylodis Macrocephalae 15 ~ 60%, Radix Saposhnikoviae 10 ~ 35%.
2. YUPINGFENG KELI according to claim 1 is in the purposes of preparation treatment medicine for nasopharyngeal, and the raw material of the medicine activity component of described YUPINGFENG KELI and mass ratio are: the Radix Astragali 60%, the Rhizoma Atractylodis Macrocephalae 20%, Radix Saposhnikoviae 20%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310446193.9A CN103479714B (en) | 2013-09-26 | 2013-09-26 | The novelty teabag of YUPINGFENG KELI |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310446193.9A CN103479714B (en) | 2013-09-26 | 2013-09-26 | The novelty teabag of YUPINGFENG KELI |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103479714A CN103479714A (en) | 2014-01-01 |
| CN103479714B true CN103479714B (en) | 2016-03-23 |
Family
ID=49820530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310446193.9A Active CN103479714B (en) | 2013-09-26 | 2013-09-26 | The novelty teabag of YUPINGFENG KELI |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103479714B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109248278A (en) * | 2018-09-28 | 2019-01-22 | 史利 | It is a kind of for treating the Chinese medicine composition of nasopharyngeal carcinoma |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1279988A (en) * | 2000-06-26 | 2001-01-17 | 黄时明 | Medicine for curing tumor |
| CN101375992A (en) * | 2007-08-29 | 2009-03-04 | 尚士光 | Immunity function excitant for treating aids |
-
2013
- 2013-09-26 CN CN201310446193.9A patent/CN103479714B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1279988A (en) * | 2000-06-26 | 2001-01-17 | 黄时明 | Medicine for curing tumor |
| CN101375992A (en) * | 2007-08-29 | 2009-03-04 | 尚士光 | Immunity function excitant for treating aids |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103479714A (en) | 2014-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105560663A (en) | Traditional Chinese medicinal composition for treating diseases caused by exogenous seasonal pathogenic factors and preparation method thereof | |
| CN103599352B (en) | The medicine for the treatment of acute pharyngolaryngitis | |
| CN101628108B (en) | Traditional Chinese medicinal granules for treating wind-cold evil and preparation method thereof | |
| CN103479714B (en) | The novelty teabag of YUPINGFENG KELI | |
| CN105126030A (en) | Zhuang medicine composition assisted in resisting lung cancer | |
| CN102028865A (en) | Medicinal composition for relieving cough and reducing sputum and method for preparing same | |
| CN103893700B (en) | A kind of Chinese medicine composition treating breast carcinoma | |
| CN105998402A (en) | Pharmaceutical preparation for treating hand-foot-mouth disease and application of pharmaceutical preparation | |
| CN102949572A (en) | Medicinal composition for treating throat diseases, and its preparation method | |
| CN103721095B (en) | Be used for preventing grippal Chinese medicine preparation | |
| CN104524277A (en) | Traditional Chinese medicine mixture for treating anorexia nervosa | |
| CN103977240A (en) | Traditional Chinese medicine medicament for treating infantile acute laryngitis and preparation method thereof | |
| CN103721058A (en) | Traditional Chinese medicine preparation for preventing influenza viruses | |
| CN103989931A (en) | Traditional Chinese medicine for treating infantile cough and preparation method thereof | |
| CN103690902B (en) | For preventing the Chinese medicine preparation of nasopharyngeal carcinoma radiation side reaction | |
| CN108434398A (en) | Treat the Chinese medicine composition and its preparation method and application of lung cancer | |
| CN101856393B (en) | Application of compound Yiganling composition in aspect of auxiliary treatment of chemotherapy of tumors | |
| CN102614268B (en) | Chinese medicine for treating esophageal carcinoma | |
| CN104524284A (en) | Medicine for preventing and treating flu | |
| CN105902874A (en) | Oral solution for treating varicella in children | |
| CN104922525A (en) | Traditional Chinese medicine composition for treating pulmonary abscess | |
| CN103599410B (en) | A kind of measles for the treatment of sends out not smooth Chinese medicine thoroughly | |
| CN104337922A (en) | Chinese medicine preparation for nursing acute tonsillitis and preparation method | |
| CN103705857A (en) | Chinese medicinal composition for preventing radioactive oral mucosa reaction | |
| CN103505501A (en) | New application of Yupingfeng particles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: Three road 528300 in Guangdong province Foshan city Shunde District of Ronggui high tech Park Keyuan cross No. 2 Patentee after: SINOPHARM GUANGDONG GLOBAL PHARMACEUTICAL CO., LTD. Address before: Three road 528300 in Guangdong province Foshan city Shunde District of Ronggui high tech Park Keyuan cross No. 2 Patentee before: Huanqiu Pharmaceutical Co., Ltd., Guangdong |